Invezz
09 Jun 2026, 09:13 UTC · 2h ago
London's FTSE 100 falls as GSK slides after Nuvalent deal
Invezz
09 Jun 2026, 09:13 UTC · 2h ago
Story key points
3 claims · impact-rated
GSK announced plans to acquire US-based drug developer Nuvalent in a deal valued at $10.6 billion. — The market reacted negatively to the deal's valuation and integration risks, leading to a 2.8% drop in GSK's share price.
-0.60UK construction sector is experiencing the sharpest cost inflation since 1997 while demand continues to contract. — Severe input cost inflation paired with falling demand creates a significant margin squeeze risk for the broader construction industry.
-0.40The FTSE 100 index declined by 0.3% on Tuesday, primarily dragged down by GSK and the pharma sector. — Reflects a short-term negative sentiment for the UK benchmark index due to concentrated losses in a major heavyweight.
-0.20Ticker attribution
Model heads
Continue reading
6 related stories
Top 1 mover · tap to explore
Shares fell and are recommended for sale due to market skepticism regarding the $10.6B Nuvalent acquisition.
Recommended as a buy due to pricing power and balance-sheet strength amidst cost inflation.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
6 dimensions · 9 clusters
Market reaction
1 bid · 10 offered
Proactive Investors
5h ago
